We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Overcoming Resistance in ALK-Positive NSCLC: The Emergence of APG-2449 as a Novel FAK and Third-Generation TKI

MedXY Editorial Team•Jan 9, 2026•news
targeted therapy

Highlights

Dual-Mechanism Efficacy

APG-2449 acts as both a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) and a focal adhesion kinase (FAK) inhibitor, addressing resistance pathways that often bypass traditional TKI therapy.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic LeukemiaThis study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survivalSep 22, 2026Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple MyelomaPKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.Sep 22, 2026Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-upA 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patientsSep 21, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Bendamustine as a Novel Single-Agent Therapy in High Burden T-Cell Large Granular Lymphocytic Leukemia: Clinical Efficacy and STAT3 Pathway Inhibition
Bendamustine monotherapy achieved high response rates and inhibited STAT3 signaling in patients with high burden T-cell large granular lymphocytic leukemia, showing promise as an effective and well-tolerated treatment option.
Sep 18, 2026
Targeting Acute Myeloid Leukemia through Multi-Functional Small Molecules: Insights from Cheminformatics and Mitochondrial ModulationCheminformatic screening identified novel small molecules with apoptotic, autophagic, and reductase-inhibitory activities that selectively kill AML cells, induce mitochondrial dysfunction, and synergize with current therapies, highlightingSep 1, 2026
Ivosidenib Monotherapy Shows Promise in IDH1 Mutated Myelodysplastic Neoplasm/Syndrome: A Phase 2 StudyIvosidenib monotherapy demonstrates substantial efficacy and safety in IDH1 mutated myelodysplastic neoplasm, especially in treatment-naïve high-risk patients, offering a new therapeutic option.Aug 28, 2026